Cargando…
Recent advances in managing systemic sclerosis
How the main components in systemic sclerosis—namely autoimmunity, vasculopathy, and fibrosis—fit together is still not sufficiently clear. However, vascular treatment options are well established, the body of evidence for the efficacy of immunomodulatory approaches is increasing, and now at least o...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000Research
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288672/ https://www.ncbi.nlm.nih.gov/pubmed/28184295 http://dx.doi.org/10.12688/f1000research.10022.1 |
_version_ | 1782504372057407488 |
---|---|
author | Aringer, Martin Erler, Anne |
author_facet | Aringer, Martin Erler, Anne |
author_sort | Aringer, Martin |
collection | PubMed |
description | How the main components in systemic sclerosis—namely autoimmunity, vasculopathy, and fibrosis—fit together is still not sufficiently clear. However, vascular treatment options are well established, the body of evidence for the efficacy of immunomodulatory approaches is increasing, and now at least one hopeful substance that may directly interfere with fibrosis is being tested. Although we still wait for important breakthroughs, there is grounds for hope that better therapeutic options will be available in the near future. |
format | Online Article Text |
id | pubmed-5288672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | F1000Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-52886722017-02-08 Recent advances in managing systemic sclerosis Aringer, Martin Erler, Anne F1000Res Review How the main components in systemic sclerosis—namely autoimmunity, vasculopathy, and fibrosis—fit together is still not sufficiently clear. However, vascular treatment options are well established, the body of evidence for the efficacy of immunomodulatory approaches is increasing, and now at least one hopeful substance that may directly interfere with fibrosis is being tested. Although we still wait for important breakthroughs, there is grounds for hope that better therapeutic options will be available in the near future. F1000Research 2017-01-30 /pmc/articles/PMC5288672/ /pubmed/28184295 http://dx.doi.org/10.12688/f1000research.10022.1 Text en Copyright: © 2017 Aringer M and Erler A http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Aringer, Martin Erler, Anne Recent advances in managing systemic sclerosis |
title | Recent advances in managing systemic sclerosis |
title_full | Recent advances in managing systemic sclerosis |
title_fullStr | Recent advances in managing systemic sclerosis |
title_full_unstemmed | Recent advances in managing systemic sclerosis |
title_short | Recent advances in managing systemic sclerosis |
title_sort | recent advances in managing systemic sclerosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288672/ https://www.ncbi.nlm.nih.gov/pubmed/28184295 http://dx.doi.org/10.12688/f1000research.10022.1 |
work_keys_str_mv | AT aringermartin recentadvancesinmanagingsystemicsclerosis AT erleranne recentadvancesinmanagingsystemicsclerosis |